Oragenics Inc. Advances ONP-002 Toward Phase IIa Concussion Trial with Strategic Q2 2025 Milestones

Oragenics Inc. (NYSE American: OGEN), a leader in the development of brain-targeted therapeutics through its proprietary intranasal delivery technology, has announced significant advancements in the second quarter of 2025. The company is on track to commence Phase IIa trials for its lead candidate, ONP-002, in the third quarter of 2025, marking a pivotal step toward offering the first FDA-approved pharmacological treatment for concussion.

The company has achieved several key milestones, including securing approval from the Human Research Ethics Committee in Australia, appointing Southern Star Research as its Contract Research Organization (CRO), and finalizing a cGMP manufacturing agreement with Sterling Pharma Solutions in the U.S. These developments underscore Oragenics' commitment to advancing ONP-002 through clinical trials and towards market approval.

Oragenics' innovative intranasal delivery platform represents a breakthrough in drug delivery, enabling rapid and targeted administration of therapeutics directly to the brain. This method bypasses systemic circulation, thereby minimizing side effects and enhancing efficacy. The technology not only holds promise for treating concussions but also has potential applications in addressing acute neurological emergencies and chronic neurodegenerative diseases.

The global nasal drug delivery market, valued for its non-invasive and efficient drug administration capabilities, is projected to surpass $40 billion by 2030. Oragenics' advancements position the company at the forefront of this growing market, with its proprietary technology offering new hope for patients suffering from neurological conditions.

For further details on Oragenics' progress and its pioneering work in neurological care, visit https://ibn.fm/vmS9r. Additional information about Oragenics Inc. and its innovative approaches to brain health can be found at https://ibn.fm/OGEN.